Abstract
The influence of Anafranil® on the symptomatology of depression has been evaluated in an open trial in 30 patients suffering from various types of depression. All the patients were hospitalized in the geriatric department of a psychiatric centre for the whole duration of the trial.
Within one week a marked decrease in the depressive symptoms was observed. This improvement reached its maximum after 3 weeks and remained at this level during the 4th week of treatment.
At a daily dose of 30 to 50 mg of Anafranil (mean: 40 mg) the results were good in 19 and moderate in 8 patients, whereas in 3 patients there was no change in their depressive state.
Anafranil was well tolerated; no abnormalities were observed in the laboratory investigations.
Get full access to this article
View all access options for this article.